Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Subscribe|Follow Us On

Bone Marrow Failure, Somatic Rescue by P53 Inactivation, and Enhanced Leukemogenesis in Germline ERCC6L2 Disease

January 6, 2026

[Blood] Using novel preclinical in vitro and in vivo model systems, investigators demonstrated that excision repair cross-complementing 6 like 2 (ERCC6L2) maintains the competitive ﬁtness of hematopoietic stem and progenitor cells by mitigating replication stress.

Mutant p53 Promotes Clonal Hematopoiesis through Generating a Chronic Inflammatory Microenvironment

January 6, 2026

[Journal of Clinical Investigation] The authors showed that inflammatory stress confers a competitive advantage to p53 mutant hematopoietic stem and progenitor cells by activating the NLRP1 inflammasome and increasing the secretion of pro-inflammatory cytokines.

Molecular and Phenotypic Blueprint of Human Hematopoiesis Links Proliferation Stress to Stem Cell Aging

January 6, 2026

[Journal of Experimental Medicine] Investigators provided a comprehensive phenotypic, transcriptional, and functional dissection of human hematopoiesis from youth to advanced age.

Shear Stress Governs Hematopoietic Stem Cell Fate to Promote Inflammation-Induced Aging

January 6, 2026

[Nature Aging] Scientists found that PIEZO1 senses shear stress in blood flow to induce HSC proliferation and myelopoiesis.

KIRA6 Restrains the Generation of Myeloid-Derived Suppressor Cells and Overcomes Resistance to Anti-PD-1 Therapy

January 6, 2026

[Cell Death & Disease] Researchers evaluated the potential of KIRA6, an inhibitor for inositol-requiring enzyme 1α kinase activity and RNase activity, to abrogate myeloid-derived suppressor cell-mediated immune suppression.

Inherited Resilience to Clonal Hematopoiesis by Modifying Stem Cell RNA Regulation

January 6, 2026

[Science] By analyzing data from patients and controls across multiple studies, scientists identified and studied the mechanism of a genetic variant that has the opposite effect, slowing down the expansion of clonal hematopoiesis and decreasing the risk of malignancy.

Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B Cell Non-Hodgkin Lymphoma

January 6, 2026

[Blood] Researchers systematically profiled genetic precursor lesions in 43 B cell non-Hodgkin lymphoma patients using complementary whole exome, targeted, and single-cell sequencing approaches.

MMS22L Is a Novel Key Actor of Normal and Pathological Erythropoiesis

January 6, 2026

[HemaSphere] Whole exome sequencing of a single patient with atypical congenital pure red cell aplasia revealed a mutation in the CDAN1 gene, typically associated with congenital dyserythropoietic anemia type 1, together with a previously unreported mutation in the MMS22L gene.

Targeting SUMOylation Triggers IFN-β–Dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia

January 6, 2026

[Molecular Cancer Therapeutics] Researchers demonstrated that targeting SUMOylation, a protein posttranslational modification, activates NK cells from both healthy donors and patients with AML.

Inflammaging and Clonal Hamatopoiesis Interplay and Their Impact on Human Disease

January 6, 2026

[Nature Reviews Molecular Cell Biology] Investigators discuss the molecular and cellular mechanisms that cause CHIP, its interplay with inflammaging, as well as the pathophysiological consequences and the translational implications for diseases that affect older individuals.

Hematopoietic Organoids: Opportunities and Challenges in Modeling Human Hematopoiesis and Diseases In Vitro

January 6, 2026

[Stem Cell Reports] The authors summarize recent progress in hematopoietic organoid (HO) construction, explore their potential applications in both basic research and clinical translation, and discuss current opportunities and remaining challenges in generating physiologically relevant HO models.

Johnson & Johnson Submits Application to the European Medicines Agency for TECVAYLI®▼ (Teclistamab) in Combination with DARZALEX® (Daratumumab) Subcutaneous Formulation for Patients with Relapsed/Refractory...

January 6, 2026

[Johnson & Johnson] Johnson & Johnson submitted application to the European Medicines Agency seeking approval for an indication extension of TECVAYLI^®▼ in combination with DARZALEX^® subcutaneous formulation for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.